| Drug General Information |
| Drug ID |
D01JXM
|
| Former ID |
DNC010833
|
| Drug Name |
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole
|
| Synonyms |
4-(2-(4-tert-butylphenylthio)ethyl)-1H-imidazole; 4-(2-(40-tert-butylphenylthio)ethyl)-1H-imidazole
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Histamine H4 receptor |
Target Info |
Inhibitor |
[2]
|
|---|
| Histamine H3 receptor |
Target Info |
Inhibitor |
[1]
|
| Cytochrome P450 2D6 |
Target Info |
Inhibitor |
[3]
|
| Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interactionhsa00980:Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Serotonergic synapsehsa00140:Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
Histamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390650:Histamine receptors
|
|
G alpha (i) signalling eventsR-HSA-211981:XenobioticsR-HSA-211981:Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP727:Monoamine Transport
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR downstream signalingWP702:Metapathway biotransformation
|
|
Tamoxifen metabolism
|
|
Oxidation by Cytochrome P450
|
|
Vitamin D Receptor Pathway
|
|
Aripiprazole Metabolic Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine MetabolismWP702:Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tryptophan metabolism
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | J Med Chem. 2010 Sep 9;53(17):6445-56.Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. |
|---|
| REF 2 | Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8. doi: 10.1016/j.bmc.2010.04.052. Epub 2010 Apr 21. |
|---|
| REF 3 | J Med Chem. 2010 May 13;53(9):3840-4.Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice. |
|---|
